Annovis Bio, Inc.
ANVSNYSE
Healthcare
Biotechnology
$2.27
+0.15(7.3%)
52W $1.22 – $5.10
Annovis Bio, Inc.
$45MMkt Cap
—Rev TTM
-$23MNI TTM
-2.1xP/E TTM
Latest Earnings
10-K
FY FY2025Mar 12, 2026Annovis Bio, Inc. reported a net loss of $28.9 million for fiscal year 2025, an increase from a $24.6 million net loss in 2024. The company generated no revenue and incurred total operating expenses of $29.7 million, primarily driven by research and development costs of $25.2 million for its Phase 3 Alzheimer's disease trial and other clinical programs. Cash used...
What Changed Recently
Fundamentals
How The Business Makes Money
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Industry Biotechnology
Company Profile
CIK0001477845
ISINUS03615A1088
CUSIP03615A108
Phone610 727 3913
Address1055 Westlakes Drive, Malvern, PA, 19312, US
SEC EDGAR